Population-based monitoring of HIV drug resistance in Namibia with early warning indicators

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 4, 2010, Pages

  Hong, Steven Y ^a   Jonas, Anna ^b   Dumeni, Efraim ^b   Badi, Alfons ^b   Pereko, Dawn ^c   Blom, Abraham ^c   Muthiani, Victor S ^c   Shiningavamwe, Andreas N ^d   Mukamba, James ^b,e   Andemichael, Ghirmay ^e   Barbara, Rony ^a   Bennett, Diane E ^f   Jordan, Michael R ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ministry of Health and Social Services   (Namibia)

^c Strengthening Pharmaceutical Systems Management Sciences for Health   (Namibia)

^d Namibia Institute of Pathology   (Namibia)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Africa; AIDS; antiretroviral agents; drug resistance; HIV

Indexed keywords

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; DRUG MANUFACTURE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL PRACTICE; MEDICAL SOCIETY; NAMIBIA; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; ENVIRONMENTAL MONITORING; HIV; HIV INFECTIONS; HUMANS; NAMIBIA; NATIONAL HEALTH PROGRAMS; PILOT PROJECTS;

EID: 78650251834     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f5376d     Document Type: Article

References (30)

1. WHO, UNAIDS, UNICEF. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector, September 2009 Progress Report; Geneva, Switzerland: WHO, UNAIDS, UNICEF; 2009. Available at http://www.who.int/hiv/pub/2009progressreport/en/index.html. Accessed July 20, 2010.
2. WHO. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: WHO; 2009. Available at: http:// www.who.int/hiv/pub/arv/advice/en/. Accessed July 20, 2010.
3. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3:e356.
4. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002;29:165-168.
5. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38:1311-1316.
6. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21: 965-971.
7. Marcellin F, Boyer S, Prothoggopopescu C, et al. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon. (EVAL survey, ANRS12-116). Trop Med Int Health. 2009;13:1470-1478.
8. Eholie S, Tanon A, Polneau S, et al. Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2007;45:355-358.
9. Tuller DM, Bangsberg DR, Senkungu J, et al. Transportation costs impede sustained adherence and access to HAART in a clinic population in Southwestern Uganda: a qualitative study. AIDS Behav. 2010;14:778-784.
10. Van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;10:464-470.
11. Bennett DE, Bertagnolio S, Sutherland D, et al. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl 2):1-13. Available at: http://www.who.int/hiv/pub/drugresistance/global
12. Jordan MR, Bennett DE, Bertagnolio S, et al. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008;13(Suppl 2): 15-23. Available at: http://www.who.int/hiv/pub/drugresistance/who- surveys/en/index.html. Accessed July 20, 2010.
13. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25-36. Available at: http://www.who.int/hiv/pub/drugresistance/recommendations-surveillance/ en/index.html. Accessed July 20, 2010.
14. Central Intelligence Agency (2009). "Namibia". The World Factbook. Available at: https://www.cia.gov/library/publications/the-world-fact- book/geos/wa.html. Accessed January 23, 2010.
15. The Republic of Namibia Ministry of Health and Social Services report on the 2008 national HIV sentinel survey. Windhoek, Namibia: MoHSS 2008. Available at http://www.healthnet.org.na/documents/reports/ 2008%20National%20HIV%20Sentinel%20Survey%20Report.pdf Accessed July 20, 2010.
16. WHO/UNAIDS. WHO/UNAIDS Report on Global AIDS Epidemic. Geneva, Switzerland: WHO/UNAIDS 2007. Available at http://data.unaids.org/pub/ epislides/2007/2007-epiupdate-en.pdf. Accessed July 20, 2010.
17. The Republic of Namibia Ministry of Health and Social Services (MoHSS) National Guidelines for Antiretroviral Therapy. 2nd ed. April 2007. Windhoek, Namibia: MoHSS 2007. Available at http://www.who.int/ hiv/amds/namibia-art- guide-2007.pdf.
18. World Health Organization. HIV Drug resistance Early Warning Indicator Briefing. April 2008.
19. HIV Drug resistance Early Warning Indicators. World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. April 2010. Available at: http://www.who.int/hiv/topics/ drugresistance/hiv-dr-early-warning-indicators.pdf. Accessed July 20, 2010.
20. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996;10:975-981.
21. Havlir DV, Eastman S, Gamst A, et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996;70:7894-7899.
22. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
23. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA. 2000;283:205-211.
24. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: A systematic review. PLoS Med. 2007;4: e298.
25. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIVAIDS. 2010;5: 70-7. Review.
26. Horstmann E, Brown J, Islam F, et al. Retaining HIV-infected patients in care: where are we? where do we go from here? Clin Infect Dis. 2010;50: 752-761.
27. Ndiaye B, Ould-Kaci K, Salleron J, et al. Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up. AIDS. 2009;23:1786-1789.
28. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96-101.
29. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5:e109.
30. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573.